Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Wednesday, 12 September 2012
- AstraZeneca wins prestigious business development award AstraZeneca won the award for Best Pharma BD&L Team at the Oxford Bioscience Network’s Annual Awards Dinner last night at The Ashmolean Museum, Oxford, UK.
- Monday, 13 August 2012
- AstraZeneca and Pfizer enter agreement for over-the-counter NEXIUM; AstraZeneca raises 2012 guidance NEXIUM 20mg retail launch targeted for 2014, subject to regulatory approval.
- Thursday, 9 August 2012
- AstraZeneca and Bristol-Myers Squibb complete expansion of diabetes alliance through Bristol-Myers Squibb’s acquisition of Amylin Pharmaceuticals AstraZeneca and Bristol-Myers Squibb today announced that following the successful completion of the acquisition of Amylin Pharmaceuticals by Bristol-Myers Squibb, AstraZeneca has made an initial payment of approximately $3.2 billion to Amylin Pharmaceuticals, now a wholly-owned subsidiary of Bristol-Myers Squibb. As previously disclosed, the payment is being made in connection with the expansion of the diabetes alliance between AstraZeneca and Bristol-Myers Squibb to incorporate the development and marketing of Amylin’s portfolio of diabetes products, and profits and losses arising from the collaboration will be shared equally.